Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF16.10B
• Dividend Yield: 1.01%
• Average Volume (3M): 415.23K
• Price to Earnings (P/E): 41.0
• Beta (1Y): 1.20
• Revenue Growth: 4.49%
• EPS Growth: 45.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 293,178
• 30 Day Avg. Volume: 415,225
• PEG Ratio: 0.80
• Price to Book (P/B): 8.93
• Price to Sales (P/S): 7.27
• P/FCF Ratio: 57.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF108.78
• Price Target Upside: 15.45% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 10

• Rating: 72 Outperform
• Price Target: CHF105.00 ▲(11.44% Upside)

Straumann Holding AG's overall stock score is driven by strong financial performance and positive earnings call highlights. However, technical indicators suggest potential bearish momentum, and the high P/E ratio indicates possible overvaluation. Challenges in China and currency impacts also weigh on the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business sustainability.

Strategic Partnerships

Strategic partnerships enhance product offerings and market position, driving innovation and competitive advantage in the orthodontic segment.

Digital Innovation

The new scanner strengthens Straumann's digital ecosystem, improving product integration and customer value, fostering long-term growth.

Negative Factors

Challenges in China

Regulatory changes in China pose significant challenges, potentially affecting revenue and market presence in a key growth region.

Currency Exchange Impact

Currency fluctuations can erode profitability and create financial uncertainty, impacting long-term financial performance.

Tariff Cost Pressure

Increased tariffs add to operational costs, potentially squeezing margins and affecting competitive pricing strategies.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG (STMN) is a leading global provider of dental implants, prosthetics, and digital solutions for dental professionals. Founded in 1954 and headquartered in Basel, Switzerland, the company operates in the dental sector, focusing on innovative solutions for tooth replacement and restoration. Its core products include dental implants, biomaterials, and CAD/CAM solutions, catering to both clinicians and dental laboratories. Straumann is committed to advancing oral health through research and development, offering a range of products that enhance the quality and efficiency of dental care.

How the Company Makes Money

Straumann generates revenue primarily through the sale of dental implants and related products, including prosthetics and biomaterials. The company operates a direct sales model as well as through a network of distributors and partners, allowing it to reach a global market. Key revenue streams include the sale of dental implant systems, digital dentistry solutions, and regenerative materials. Additionally, Straumann has established strategic partnerships and collaborations with dental professionals, research institutions, and other industry players to enhance its product offerings and market reach. The company's focus on innovation, evidenced by significant investment in research and development, further contributes to its ability to capture market share and drive revenue growth.

Straumann Holding AG Financial Statement Overview

Summary

Straumann Holding AG shows strong financial performance with consistent revenue growth and a solid balance sheet. However, rising operational costs and liabilities are areas to monitor.

Income Statement

Straumann Holding AG has demonstrated consistent revenue growth with a solid increase from 2023 to 2024. Gross Profit Margin is strong, indicating effective cost management. However, there is a slight decline in EBIT and EBITDA margins, suggesting rising operating costs or increased competition.

Balance Sheet

The company's balance sheet is stable with a moderate Debt-to-Equity ratio, reflecting balanced leverage. The Return on Equity is healthy, indicating efficient use of equity. The Equity Ratio is solid, showing a strong financial position, although the increase in total liabilities warrants monitoring.

Cash Flow

The cash flow is robust with a stable Free Cash Flow, reflecting the company's good cash generation capacity. There is a slight decline in Operating Cash Flow, which could be a sign of higher operational expenses. The Free Cash Flow to Net Income ratio is favorable, indicating efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.58B	2.50B	2.41B	2.32B	2.02B	1.43B
Gross Profit	1.83B	1.78B	1.79B	1.70B	1.53B	1.03B
EBITDA	850.33M	726.15M	685.07M	685.37M	591.48M	230.45M
Net Income	392.72M	388.32M	246.07M	434.79M	396.08M	91.28M
Balance Sheet
Total Assets	3.51B	3.62B	3.40B	3.45B	3.05B	2.62B
Cash, Cash Equivalents and Short-Term Investments	246.53M	383.07M	413.54M	697.11M	881.50M	632.49M
Total Debt	411.27M	413.89M	412.35M	705.20M	711.66M	731.66M
Total Liabilities	1.45B	1.58B	1.56B	1.60B	1.55B	1.41B
Stockholders Equity	2.06B	2.04B	1.84B	1.85B	1.50B	1.20B
Cash Flow
Free Cash Flow	351.32M	315.62M	316.61M	220.94M	440.97M	295.34M
Operating Cash Flow	500.77M	483.39M	503.95M	416.38M	561.94M	377.41M
Investing Cash Flow	-392.95M	-352.62M	-349.33M	-449.84M	-185.20M	-145.64M
Financing Cash Flow	-180.68M	-169.06M	-424.40M	-140.35M	-122.90M	153.33M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 94.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Positive. The current price of 94.22 is above the 20-day moving average (MA) of 89.73, above the 50-day MA of 90.74, and below the 200-day MA of 104.87, indicating a neutral trend. The MACD of 1.36 indicates Negative momentum. The RSI at 74.11 is Negative, neither overbought nor oversold. The STOCH value of 84.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STMN	―	CHF16.10B	41.00	―	1.01%	4.49%	45.08%
SOON	―	CHF12.84B	24.67	―	1.97%	6.58%	-10.02%
GALD	―	CHF32.15B	99.08	―	0.10%	6.22%	―
ALC	―	$29.85B	31.38	4.98%	0.47%	1.60%	-4.40%
SKAN	―	CHF1.19B	73.80	―	0.78%	-3.45%	-49.82%
MED	―	CHF1.09B	282.78	―	―	7.29%	-112.70%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Straumann Holding AG Corporate Events

Straumann Holding’s Earnings Call Highlights Growth Amid Challenges

The recent earnings call for Straumann Holding conveyed a generally positive sentiment, underscored by robust revenue growth, strategic alliances, and successful operational strides. However, the company acknowledged some challenges, particularly in China due to VBP 2.0, alongside currency exchange and tariff pressures that posed notable hurdles.

Straumann Group Reports Strong Q3 Growth and Confirms 2025 Outlook

Straumann Group reported strong organic growth of 8.3% in the third quarter of 2025, with revenue reaching CHF 602.2 million. The company confirmed its outlook for 2025, aiming for high single-digit organic revenue growth despite tariff impacts. Key growth regions included EMEA and Latin America, while North America showed improvement and Asia-Pacific faced challenges in China. Strategic partnerships in orthodontics and the launch of the SIRIOS X3 intraoral scanner are expected to enhance innovation and market positioning.

The most recent analyst rating on (CH:STMN) stock is a Sell with a CHF80.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Group Transforms Orthodontics Business with Strategic Partnerships

Straumann Group has announced new strategic partnerships to transform its orthodontics business, focusing on innovation, key markets, and operational excellence. By partnering with Smartee and DentalMonitoring, Straumann aims to enhance its ClearCorrect brand’s positioning, improve efficiency, and increase profitability, thereby strengthening its competitiveness in the global orthodontics market.

The most recent analyst rating on (CH:STMN) stock is a Sell with a CHF80.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Raises CHF 250 Million Through Successful Bond Issuance

Straumann Holding AG has successfully raised CHF 250 million through a three-year bond issuance, with the proceeds intended for refinancing an existing bond and general corporate purposes. This strategic financial move, supported by UBS AG and Zürcher Kantonalbank, is expected to bolster Straumann’s operational capabilities and maintain its strong market position in the dental solutions industry.

The most recent analyst rating on (CH:STMN) stock is a Hold with a CHF113.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann’s Earnings Call: Strong Growth Amid Challenges

During Straumann Holding’s latest earnings call, the company conveyed a positive sentiment, underscoring strong revenue growth, successful product launches, and strategic investments. Despite facing challenges from currency fluctuations and tariffs, the company expressed confidence in its strategic outlook and growth potential, driven by recent product innovations and market expansions.

Straumann Reports Strong Half-Year Results and Confirms 2025 Outlook

Straumann Holding AG reported strong half-year results with sales reaching CHF 1.3 billion, reflecting a 10.2% organic growth. Despite challenges like unfavorable currency developments, the company maintained a robust core EBIT margin and confirmed its 2025 outlook. Key product launches, including the iEXCEL implant system and MIDAS 3D printer, have gained momentum, supporting Straumann’s strategic focus on digital transformation and capacity expansion. The company’s broad-based growth across all regions and business segments underscores its strong market positioning and commitment to innovation.

The most recent analyst rating on (CH:STMN) stock is a Hold with a CHF143.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.